Not yet recruiting NCT07635043
Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Betamethasone Dipropionate 0.05% Cream, Tapinarof Cream 1%.
- Who it may be relevant to
- Registry conditions: Psoriasis (PsO). Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Pakistan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad
Interventions
- Drug Betamethasone Dipropionate 0.05% Cream
Topical betamethasone dipropionate 0.05% cream once daily applied to affected plaque psoriasis lesions twice daily for up to 4 weeks - Drug Tapinarof Cream 1%
Topical tapinarof 1% cream applied once daily to affected skin areas for up to 12 weeks
Primary outcome measures
- Percentage of participants achieving a 75% reduction from baseline in psoriasis area and severity index(PASI 75) [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- Age 18 years-65 years
- Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)
- Disease duration of at least 6 months
- Willing and able to provide written informed consent
- Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies)
Exclusion criteria
- Severe psoriasis (BSA >20% or requiring systemic therapy)
- Pregnant and lactating mothers
- Known hypersensitivity to Tapinarof or any of its excipients
- Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis
- Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment
- History of malignancy or current active infection
- Known hypersensitivity to betamethasone or Tapinarof
- Use of powerful topical corticosteroids within two weeks previously
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Pakistan · 1 center
- Pakistan institute of medical sciences(PIMS) — Islamabad
Identifiers
NCT: NCT07635043 · Tapinarof vs betamethasone